MDRNA CEO Michael French has been appointed to the company’s board, and has also been named as president.
French joined MDRNA, which previously was known as Nastech Pharmaceutical (see RNAi News, 6/12/2008), in June. He previously served as senior vice president of corporate development at Sirna Therapeutics.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
